COVID-19, the disease caused by the newly-discovered SARS-CoV-2 virus, has quickly spread from China throughout the world since January 2020. Its potential severity, despite in a minority of cases, has paralysed healthcare systems struggling for adequate resources, as well as entire nations often forced to adopt radical measures, such as lockdowns and surveillance, to contain the disease and restrict its spread. Initially presenting as a respiratory infectious disease, it can not only progress to an acute respiratory distress syndrome, but also have multisystemic consequences. There are many proving theories as regards to the pathophysiology and there are currently no proven definitive treatments. Due to its high transmissibility and the risk of infecting healthcare workers, hospitals also had to rethink their organisation. We have completed a literature review of the sixteen months of the pandemic, with attention to pathophysiology, key epidemiological concepts, hospital organisation, critical care considerations, and finally current and prospective treatments.
Download full-text PDF |
Source |
---|
Arch Rehabil Res Clin Transl
December 2024
Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN.
Objective: To provide insights from patients and clinicians regarding the benefits and barriers of the introduction of a telerehabilitation fitness program into the oncologic care of people with late-stage cancer.
Design: This study is a qualitative assessment of the COllaborative Care to Preserve PErformance in Cancer trial, which involved the insertion of a telerehabilitation fitness program into the oncologic care of patients with late-stage cancer.
Setting: A large midwestern medical center.
Rheumatology (Oxford)
January 2025
Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
Objective: Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis that exhibits a wide spectrum of clinical manifestations. The recent identification of activating mutations in the MAPK-ERK pathway in patients with ECD has led to the introduction of targeted therapies. The most commonly used targeted therapies are BRAF- and MEK-inhibitors, which are highly effective but also carry significant toxicity.
View Article and Find Full Text PDFKidney Int Rep
January 2025
Australian Frailty Network, The University of Queensland, Brisbane, Australia.
Introduction: The GOAL trial, a cluster randomized controlled trial, investigated the effect of comprehensive geriatric assessment (CGA) on frail older people with chronic kidney disease (CKD). This paper describes the following: (i) participant baseline characteristics, and (ii) their relationship with CKD stage and frailty severity.
Methods: Sixteen kidney outpatient clinics (clusters) were randomly allocated 1:1 to CGA or usual care.
J Oral Facial Pain Headache
June 2024
Department of Dentistry, Brazilian Centre for Evidence Based Research, Federal University of Santa Catarina, 88040-900 Florianópolis, SC, Brazil.
To synthesize scientific knowledge regarding the prevalence of neuropathies and nerve injuries caused by dental implant placement in mandible and the available management. Observational and interventional studies evaluating neuropathies occurrence in adults who underwent dental implant surgery were included. Any neuropathy diagnostic was accepted.
View Article and Find Full Text PDFJ Stroke Cerebrovasc Dis
January 2025
University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address:
Background: Intravenous alteplase (ALT) is the standard treatment for acute ischemic stroke (AIS). However, recent trials comparing other tissue plasminogen activators (tPAs) like tenecteplase (TNK) and reteplase with ALT have yielded conflicting results. This necessitated a network meta-analysis to compare the efficacy and safety of various tPAs in AIS patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!